Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
UK urged to refrain from meddling in HK affairsXi calls for building broad consensusCongressional threat of TikTok ban a living example of protectionism, panChairman of Foreign Affairs Committee named NPC spokesmanU.S. must step up efforts in strengthening ChinaDPRK top leader attends special concert by Chinese traditional orchestraChinese wholeNew cultural buildings open in capital's subXi replies to letter from counterChina emphasizes neighborly cooperation in diplomacy: NPC spokesman
1.7759s , 4666.9921875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Earthly Insights news portal